Oysters are widely consumed seafood, but their shells impose a serious environmental problem. To extend the utilization of oyster shell waste, we investigated the biological role of oyster shell extract. In this study, we verified that the ethanol extract of oyster shell (EOS) contains taurine and betaine, the major components of oyster body. EOS downregulated transcription of Sptlc1 and Sptlc2 mRNA, the subunits of serine palmitoyltransferase (SPT). Suppression of SPT subunits reduced sphinganine and sphingomyelin by inhibiting de novo sphingolipid biosynthesis. Inhibition of sphingomyelin biosynthesis resulted in downregulation of lipogenic gene expression such as ACC, FAS, SCD1, and DGAT2. Consistent with inhibition of lipogenesis, cellular triglyceride levels were diminished by EOS, but cholesterol levels were not altered. Taken together, these results suggest that EOS has a lipid-lowering effect and could be applied as either a therapeutic or preventive measure for metabolic dysfunction. Figure 3: Expression of serine palmitoyltransferase subunits, Sptlc1 and Sptlc2, and measurement of sphingolipids in Hepa1c1c7 cells. Cells were treated with 50 and 100 µg/mL of either 30% or 50% ethanol EOS for 16 h. mRNA levels of Sptlc1 and Sptlc2 were measured by quantitative RT-PCR (A). Cell lysates were separated by SDS-PAGE, followed by Western blot analyses of Sptlc1 and Sptlc2 (B). Sphinganine and SM were analyzed using LC-MS/MS, as described in Methods (C, D). Results are mean ± SEM. n=3. *p<0.05.
Lipid accumulation is associated with a number of illnesses including non-alcoholic fatty liver disease, type 2 diabetes-reduced insulin secretion and insulin resistance, and cardiomyopathy [1] [2] [3] . Several mechanisms have been proposed to explain how lipid accumulation by elevated fatty acids (FA) leads to organ dysfunction. Among them, a hypothesis that is gaining credibility is that excess lipid accumulation and synthesis of lipid metabolites in non-adipose tissues disrupt metabolic balance. One alternative route to utilize excess FA is via the sphingolipid biosynthetic pathway. Dysregulation of this by excess FA uptake produces signaling lipids including ceramide and sphingomyelin (SM). Previous reports suggest that inhibition of SM synthesis reduces hepatic triglyceride (TG) and cholesterol biosynthesis, which reduces atherosclerosis in ApoE-deficient mice [4, 5] . Thus, inhibition of de novo sphingolipid biosynthesis has been suggested as a therapeutic target for hyperlipidemia and insulin resistance [4] [5] [6] .
Epidemiological studies demonstrated that daily seafood intake helps reduce mortality and risk of cardiovascular disease [7, 8] . Intake of the non-lipid fractions of seafood from short-necked clam, squid, shrimp, and octopus resulted in beneficial effects by lowering lipid levels in the serum and liver of mice and rats [9, 10] . In addition to these organisms, the consumption of defatted oyster meat exerts hypolipidemic activity as well, and this effect can be ascribed to both the lipid and non-lipid fractions [11] . Chronic feeding of oyster improves glucose tolerance in alloxan-induced diabetic rats [12] .
Oyster is a popular seafood with a high nutritious value and is consumed widely worldwide. In near-shore fisheries, oyster is a dominant product and provides a high-profit to the seafood industry. However, oyster farming produces an enormous amount of oyster shells, approximately 90% of which are thrown away as waste, which results in serious environmental problems [13, 14] . To prevent this, oyster shells have been utilized for construction materials after crushing, and as shell meal fertilizer [15] . The chemical composition of oyster shell is mostly CaCO 3 (>95%) with other minerals in low amount [15] . However, the other components and their functional roles have not been characterized yet. In northeast Asian countries, including Korea, Japan, and China, oyster shell has been utilized traditionally as an antacid medicine. In 16th century medical literature published in China, oyster shells were reported to treat skin dermatitis. Currently, oyster shells are being consumed as a calcium supplement [16] .
In this study, we hypothesized that there are biologically active components in oyster shell that characterized its function in regulation of lipid metabolism. Expression of serine palmitoyltransferase subunits, Sptlc1 and Sptlc2, were downregulated by oyster shell extract (EOS) treatment in hepa1c1c7 cells. As a result, sphinganine and SM were reduced, which downregulated the genes involved in FA and TG synthesis. Suppression of lipogenic genes led to decreased TG levels in hepa1c1c7 cells after EOS treatments. These observations suggest that EOS has a TG-lowering effect via suppression of de novo sphingolipid biosynthesis.
Measurements of representative components in oyster shell:
Oyster shells are mostly composed of CaCO 3 (more than 95% contents), which supports the protective shell structure physically [17] . Previous study reported taurine and betaine in oyster muscle block [17] . Taurine (2-aminoethanesulfonic acid) is an organic acid widely found in various animal tissues. It has many fundamental biological functions including bile acids, antioxidation, osmoregulation, membrane stabilization, and modulation of calcium signaling [18] . In addition, betaine (trimethylglycine) is a dietary component, and farm animal studies showed that inclusion of betaine in feed produced leaner meat with a lower fat content [19] . Both of these components are known to have a lipid-lowering effect and improve diabetic conditions [18] .
We examined the optimal extraction efficiency of taurine and betaine by ethanol extraction of oyster shells at various concentrations (0, 30, 50, and 70% ethanol). Taurine and betaine had HPLC retention times of 2.1 and 3.9 min, respectively. The highest concentration of betaine (2.01 mg/g) was found in the 70% (Table 1) , whereas the highest concentration of taurine was found in the 50% ethanol extract (4.51 mg/g) ( Table 1) . The optimal percentage of ethanol for extraction of taurine from oyster shell was 30%, and of betaine 50%. We found that betaine and taurine, major components in oyster body, were also found in oyster shell. 
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Viability of oyster shell extract-treated cells:
The cytotoxic effect of the ethanol extract of oyster shell (EOS) was examined in murine hepa1c1c7 hepatoma cells after 24 and 48 h. In this experiment, both 30% and 50% EOS were chosen because the biological efficacy was only found using these two. We found that EOS did not cause significant cytotoxicity up to 200 μg/mL, but decreased cell viability by 25% and 37% when treated with 1000 μg/mL of 30% and 50% EOS, respectively, after 24 h treatment ( Figure 1 ). After 48 h of 1000 μg/mL EOS treatment, both EOS decreased cell viability by 40%. These results suggested that EOS extracted by 30% and 50% ethanol did not cause cytotoxicity up to 200 μg/mL.
Inhibition of de novo sphingolipid biosynthesis:
Hepatic lipogenesis and lipoprotein metabolism is central to whole body metabolism, playing a role in lipid delivery to peripheral tissues and clearance of remnant lipoproteins. We performed experiments with hepatic cells and examined the effects of EOS on hepatic lipogenesis. Previous findings suggested that SPT inhibits de novo sphingolipid biosynthesis in liver and that low levels of SM reduce hepatic biosynthesis of TG and cholesterol [4, 5] . To determine whether EOS treatment affects de novo sphingolipid biosynthesis, we measured mRNA and protein expression of the SPT subunits, Sptlc1 and Sptlc2. Indeed, transcription of Sptlc1 was suppressed by 30% EOS, and Sptlc2 by 50% EOS (Figure 2A ). Interestingly, while neither EOS altered Sptlc1 protein levels, Sptlc2 protein levels were reduced by EOS treatment ( Figure 2B ). The degree of Sptlc2 suppression was more prominent with 50% EOS. Consistent with different protein results, cellular sphinganine (a product of SPT reaction) and SM (a final product of sphingolipid biosynthesis) were diminished in hepa1c1c7 cells by 50% EOS (Figure 2C ). However, the representative components in oyster body, betaine and taurine, did not alter SPT expression (data not shown), which suggests that there could be other novel components in EOS regulating sphingolipid biosynthesis. These results indicate that EOS has a suppressing effect on Sptlc2 and inhibits sphingolipid biosynthesis.
Suppression of FA lipogenic gene expression:
To examine whether Sptlc2 downregulation and reduced SM affect lipogenesis, we measured expression of the genes involved in FA/TG biosynthesis. EOS downregulated expression of acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl CoA synthetase-1 (SCD1), and diacylglycerol acyltransferase 2 (DGAT2) (Figure 3 ). However, expression of HMG CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis, was not changed (data not shown). Interestingly, the degree of gene suppressing effects was slightly greater with 50% EOS in SCD1 and DGAT2 than with 30% EOS. This difference might be due to decreased cellular SM levels, which were more prominent with 50% EOS. Thus, suppression of Sptlc2 resulted in downregulation of lipogenic genes, possibly leading to TG reduction. 
Reduced TG biosynthesis by EOS:
Suppression of lipogenic gene expression implied that cellular TG might be regulated by EOS. To determine whether downregulated expression of lipogenic genes leads to decreased cellular TG, we measured cellular TG biochemically. While TG levels were not changed by 30% EOS, 50% EOS reduced cellular TG by 60% at 100 μg/mL concentration (Figure 4 ). Taken together, suppression of Sptlc2 by EOS inhibited lipogenesis and resulted in decreased TG.
In conclusion, ethanol extract of C. gigas oyster shell provided an inhibitory efficacy of de novo sphingolipid biosynthesis by suppressing Sptlc2, a subunit of serine palmitoyltransferase. As a result, reduced SM inhibited hepatic lipogenesis suppressed TG biosynthesis. In addition to current uses of discarded oyster shell as construction materials and calcium supplement, the usage of oyster shell wastes could be extended to prevent chronic metabolic diseases by its lipid-lowering effect.
